All In Biotech

Drug Trial Radar · NCT06883630

A Phase Ib Study of RC148 as Monotherapy or Combination for Locally Advanced or Metastatic NSCLC

A Phase Ib, Multi-Cohort, Open-Label, Multi-Center Clinical Trial to Evaluate the Efficacy and Safety of RC148 Injection as Monotherapy or Combination Therapy in Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer.

Last checked: Nov 19, 2026Latest source record: Mar 5, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruitingPivotal-lookingRandomized with 121 participants. This is a heuristic, not a regulatory label.

Status

Active, not recruiting

Enrollment

121

Actual

Start

Mar 13, 2025

Primary completion

Aug 31, 2026

Study completion Jul 31, 2027

Sponsor

Lead sponsor
RemeGen Co., Ltd.Industry
Sponsor type
Industry
First posted
Mar 19, 2025

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Randomized
Model
Parallel
Masking
Single (participant)
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 80 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This study will evaluate the efficacy, safety, pharmacokinetics and immunogenicity of RC148 injection as a single agent or in combination for the treatment of locally advanced or metastatic non-small cell lung cancer

Conditions

  • Non-Small Cell Lung Cancer

Interventions

  • RC148 plus Carboplatin and Paclitaxel/pemetrexedDrug

    RC148; Carboplatin; Paclitaxel; pemetrexed

  • RC148Drug

    RC148 Monotherapy

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Objective Response Rate (ORR)Time frame: 24 months

Locations

24 sites in 1 country. Site status is shown where the registry gives one.

  • Beijing Tiantan Hospital of Capital Medical University

    Beijing, Beijing Municipality, China

  • Peking University Cancer Hospital

    Beijing, Beijing Municipality, China

  • Shunde Hospital of Southern Medical University

    Foshan, Guangdong, China

  • The First People's Hospital of Shunde

    Foshan, Guangdong, China

  • Sun Yat-sen University Cancer Center

    Guangzhou, Guangdong, China

  • The First affiliated Hospital of Guangzhou Medical University

    Guangzhou, Guangdong, China

  • Jiangmen Central Hospital

    Jiangmen, Guangdong, China

  • The Second Affiliated Hospital of Guilin Medical College

    Gulin, Guangxi, China

  • Affiliated Cancer Hospital of Guangxi Medical University

    Nanning, Guangxi, China

  • Harbin Medical University Cancer Hospital

    Harbin, Heilongjiang, China

  • Nanyang Second General Hospital

    Hanyang, Henan, China

  • The First Affiliated Hospital of Xinxiang Medical College

    Xinxiang, Henan, China

  • Henan cancer hospital

    Zhengzhou, Henan, China

  • Union Hospital Tongji Medical College Huazhong University Of Science And Technologe

    Wuhan, Hubei, China

  • Hunan Cancer Hospital

    Changsha, Hunan, China

  • The Affiliated Hospital of Xuzhou Medical University

    Xuzhou, Jiangsu, China

  • Shengjing Hospital of China Medical University

    Shenyang, Liaoning, China

  • Binzhou Medical University Hospital

    Binzhou, Shandong, China

  • Jinan Central Hospital

    Jinan, Shandong, China

  • Linyi Cancer Hospital

    Linyi, Shandong, China

  • Tianjin Medical University Cancer Institute Hospital

    Tianjin, Tianjin Municipality, China

  • Yunnan Cancer Hospital

    Kunming, Yunnan, China

  • Zhejiang Cancer Hospital

    Hangzhou, Zhejiang, China

  • Taizhou Hospital of Zhejiang Province

    Taizhou, Zhejiang, China

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.